Latest News

A machine learning-triggered nephrology consultation did not reduce peak creatinine changes in hospitalized patients at high risk for stage 2 AKI.

The new drug application's submission is supported by data from the phase 3 clinical studies SynAIRgy and LunAIRo.

In an interview with Pharmacy Times, Manale Maksour, PharmD, BCOP, BCPS, discussed the patient selection, standardized workflows, toxicity management, payer coordination, and caregiver education needed to safely move bispecific step-up dosing into the outpatient setting.

Understanding OTC oral and topical treatment options, plus lifestyle steps, helps pharmacists guide safer relief.

New data show mRNA-1010 diversifies B-cell responses well beyond what conventional hemagglutination-inhibition testing can capture.

In an interview with Pharmacy Times, Cherise Steib, PharmD, HDDP, discussed patient selection, caregiver requirements, cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and the American Oncology Network’s approach to building an outpatient bispecific therapy program.

Some commonly used treatments for chronic low back pain may offer limited benefit while increasing risks, underscoring the need for pharmacists to support evidence-based, patient-centered care.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS (AQ-Cardiology), CACP, led a Pharmacy Times Clinical Forum on optimizing the management of patients with heart failure across practice settings.

Baseline proton pump inhibitor (PPI) use—and to a lesser extent antibiotic use—was associated with reduced benefit from consolidation durvalumab after chemoradiotherapy in patients with unresectable stage 3 NSCLC.

New PET imaging data show reduced dopamine nerve terminal density in patients with long COVID, correlating with fatigue, motor slowing, and memory problems.

Two clinicians—a psychiatric prescriber and a hospital clinical pharmacist—weigh in on when to add a glucagon-like peptide-1 receptor agonist for patients with serious mental illness, how to monitor for trouble, and how to set expectations at the counter.

AI functions as a supportive layer that improves efficiency while preserving the pharmacist’s central role in therapeutic decision-making.

Pharmacists proactively identify red flags for early detection, navigate complex insurance and access barriers for high-cost disease-modifying therapies, and serve as educators across settings.

Patients with cancer on semaglutide or tirzepatide face hidden drug-drug interactions such as slowed absorption and nausea, requiring antiemetics and pharmacist coordination.

The 20-mg once-daily tablet is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C).

Outpatient BiTE therapy for multiple myeloma may be safely supported in community oncology settings through careful patient selection, pharmacist-led coordination, home monitoring, caregiver education, and standardized protocols for managing CRS and ICANS.

Explore emerging flu antivirals, from season-long CD388 prevention to single-dose therapies, designed to beat current treatment limits.

If approved, AXS-12 would be a potentially valuable new option for a symptom that significantly impairs the daily functioning of those with narcolepsy.

Compared with conventional imaging alone, patient-reported outcomes integrated with machine learning may provide an earlier indication of breast cancer recurrence, disease progression, and survival.

A simplified, no-cost machine learning version of the Martin-Hopkins equation matched the original's accuracy across millions of blood samples, helping clinicians identify patients who qualify for lipid-lowering therapy.

Get engaged or get left out.